{"id":"dose-1-ibi302","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to increased activation and proliferation of T-cells, which can recognize and kill cancer cells. IBI302 has shown promise in treating various types of cancer by enhancing anti-tumor immune response.","oneSentence":"IBI302 is an anti-PD-1 monoclonal antibody that works by binding to the PD-1 receptor and blocking its interaction with PD-L1, thereby enhancing T-cell mediated immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:01.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT03814291","phase":"PHASE1","title":"A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-04-15","conditions":"Neovascular Age-related Macular Degeneration","enrollment":31},{"nctId":"NCT04820452","phase":"PHASE2","title":"A Study of IBI302 in Patients With nAMD","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-04-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":231},{"nctId":"NCT05403749","phase":"PHASE2","title":"A Study of Longer Interval of IVT IBI302 in Subjects With nAMD","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-06-29","conditions":"Neovascular Age-related Macular Degeneration","enrollment":132},{"nctId":"NCT05961007","phase":"PHASE1, PHASE2","title":"Evaluation of IBI302 Injection in nAMD or DME","status":"SUSPENDED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-11-18","conditions":"Neovascular Age-related Macular Degeneration, Diabetic Macular Edema","enrollment":234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"dose 1 IBI302","genericName":"dose 1 IBI302","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"IBI302 is an anti-PD-1 monoclonal antibody that works by binding to the PD-1 receptor and blocking its interaction with PD-L1, thereby enhancing T-cell mediated immune response. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}